KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $357.8 million.

  • Halozyme Therapeutics' Net Cash Flow rose 116660.7% to $357.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.3 million, marking a year-over-year increase of 32129.03%. This contributed to the annual value of -$2.5 million for FY2024, which is 9783.37% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Net Cash Flow is $357.8 million, which was up 116660.7% from -$114.5 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Net Cash Flow peaked at $357.8 million during Q3 2025, and registered a low of -$373.0 million during Q4 2021.
  • In the last 5 years, Halozyme Therapeutics' Net Cash Flow had a median value of $23.2 million in 2024 and averaged $14.3 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Net Cash Flow soared by 239016.86% in 2021, and later crashed by 1548959.28% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Net Cash Flow stood at -$373.0 million in 2021, then skyrocketed by 123.34% to $87.0 million in 2022, then plummeted by 279.07% to -$155.9 million in 2023, then skyrocketed by 75.32% to -$38.5 million in 2024, then skyrocketed by 1030.13% to $357.8 million in 2025.
  • Its Net Cash Flow was $357.8 million in Q3 2025, compared to -$114.5 million in Q2 2025 and $60.5 million in Q1 2025.